Antibody engineering to develop new antirheumatic therapies

Antibody engineering to develop new antirheumatic therapies

There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment, with many more patients achieving disease remission. There is even a prevailing sense that dise...

Health economics: implications for novel antirheumatic therapies.

UNLABELLED This paper discusses the pharmacoeconomics issues relating to the use of the newer therapies for rheumatoid arthritis (RA), namely the tumour necrosis factor (TNF) inhibitors. RESULTS of recent studies have provided some evidence regarding the cost effectiveness of these agents. However, as the use of TNF inhibitors evolves--including their use in other systemic inflammatory diseas...

Q10uest for New Therapies to Prevent Antiphospholipid Antibody-Mediated Thrombosis.

Although the antiphospholipid syndrome (APS) has been clearly defined for over 3 decades, it remains a clinical challenge. Treatment of this syndrome, the association of certain autoantibodies with thrombosis and recurrent pregnancy loss, is on one hand straightforward. Patients who have had a thrombotic event and persistently positive antiphospholipid antibodies (aPL) are at high risk for recu...

A Method to Develop Interactive Environments to Support Occupational Therapies

Physical therapy is not limited to a simple rehabilitation procedure; this paper proposes a method for production of interactive environments in order to support the recovery process for people with temporary physical disability. The proposed method preconizes the rehabilitation as a set of ordered steps, taking into account best practices in occupational therapy coming from several actors invo...

An Engineering Approach to Develop Business Networks